Uridine
Based on 22 publication(s) in Google Scholar
Uridine (β-Uridine) is a nucleoside compound composed of uracil and a ribose ring, which are connected by a β-N1-glycosidic bond.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.97%
- CAS. Nr.: 58-96-8
- Formel: C9H12N2O6
- Molecular Weight:244.20
-
Speicherung:
Store at room temperature 3 years.
In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Uridine
More- Imeta. 2026 Feb 24.
- Bioact Mater. 2025 Feb 13:48:55-70. [Abstract]
- Autophagy. 2026 Jul;22(7):1657-1678. [Abstract]
- Nat Commun. 2026 Feb 25;17(1):3142. [Abstract]
- J Adv Res. 2025 May 10:S2090-1232(25)00309-1. [Abstract]
- Cell Death Differ. 2024 Feb;31(2):239-253. [Abstract]
- Oncogene. 2025 May;44(16):1078-1092. [Abstract]
- Cell Prolif. 2023 Sep;56(9):e13442. [Abstract]
- Int J Mol Sci. 2023 Mar 7;24(6):5093. [Abstract]
- Pestic Biochem Physiol. 2026 Jun:221:107096. [Abstract]
- Aquaculture. 2025 Feb 15.
- J Virol. 2025 Nov 25;99(11):e0098525. [Abstract]
- Mol Immunol. 2026 May 23:195:198-208. [Abstract]
- ACS Chem Biol. 2026 Mar 20;21(3):601-612. [Abstract]
- J Pharm Biomed Anal. 2025 Nov 15:265:117026. [Abstract]
- Biochem Biophys Res Commun. 2026 Jan 8:795:153117. [Abstract]
- bioRxiv. 2025 Nov 20.
- Cell Investig. 2025 Sep 30.
- bioRxiv. 2025 Aug 22.
- Res Sq. 2025 May 12.
- Biomed Pharmacother. 2019 Oct:118:109305. [Abstract]
- Biomed Pharmacother. 2019 Aug:116:108982. [Abstract]
Customer Validation & Images
-
Bio/Physico-chemical Assay
-
WB
-
WB
-
Cell Migration/Invasion Assay
-
WB
Alle Endogenous Metabolite Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
|
Human Endogenous Metabolite |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CCRF-CEM | IC50 |
>200 μM
Compound: araU
|
Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
Compound was evaluated for its antiproliferative activity on human T-lymphocyte CEM cells
|
10.1016/S0960-894X(97)00044-9 |
| H9 | EC50 |
10 μg/mL
Compound: uridine
|
Antiviral activity against HIV1 3B infected in human H9 cells after 4 days by p24 antigen ELISA assay
Antiviral activity against HIV1 3B infected in human H9 cells after 4 days by p24 antigen ELISA assay
|
[PMID: 7775984] |
| L1210 | IC50 |
>200 μM
Compound: araU
|
Tested for its antiproliferative activity on murine leukemia L1210 cells
Tested for its antiproliferative activity on murine leukemia L1210 cells
|
10.1016/S0960-894X(97)00044-9 |
| MOLT-4 | IC50 |
>200 μM
Compound: araU
|
Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
Compound was evaluated for its antiproliferative activity on human T-lymphocyte Molt4/C8 cells
|
10.1016/S0960-894X(97)00044-9 |
| RAW264.7 | IC50 |
>10 μM
Compound: 21
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
Antiinflammatory activity in mouse RAW264.7 cells assessed as reduction in LPS-induced NO production pretreated for 30 mins followed by LPS stimulation for 24 hrs by Griess assay
|
[PMID: 28499733] |
Uridine (6-24 mM, 7 days) inhibits the proliferation of leukemia cell HL-60, arrests the cell cycle at G2/M phase, and induces the differentiation of HL-60 into mature cells with characteristics of monocytes and granulocytes[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HL-60
-
Concentration:6-24 mM
-
Incubation Time:7 days
-
Result:Inhibited the cell proliferation.
Uridine (30 mg/kg, iv, single dose) exhibits anti-ischemic, antixoxidant and anti-arrhythmic effcts in rats models, exhibits protective efficacy against acute myocardial ischemia and ischemia/reperfusion injury[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Mouse liver fibrosis models[2]
-
Dosage:10-20 mg/kg
-
Administration:oral, 6 weeks
-
Result:Reduced levels of ALP, ALT and AST in serum, decreased the collagen deposition.
-
Animal Model:Rats acute myocardial ischemia (AMI) and ischemia/reperfusion (I/R) models[3]
-
Dosage:30 mg/kg
-
Administration:iv, single dose
-
Result:Inhibited ischemia-induced lipid peroxidation, reduced the ischemic area, duration of ischemia-induced arrhythmias, the occurrence of premature ventricular beats (PVB) and ventricular tachycardia (VT).
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 58-96-8
-
Appearance Solid
-
Molecular Weight 244.20
-
Formel C9H12N2O6
-
Color White to off-white
-
SMILES
O[C@H]1[C@@H](O)[C@H](N2C(NC(C=C2)=O)=O)O[C@@H]1CO
-
Synonyms
β-Uridine
-
Structure Classification
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Store at room temperature 3 years
In solvent -80°C 2 years -20°C 1 year
Publications (22)
-
Journal Impact Factor
-
Most Recent
-
-
Bioact Mater
cGAMP-targeting injectable hydrogel system promotes periodontal restoration by alleviating cGAS-STING pathway activation. [Abstract]2025 Feb 13:48:55-70. PMID: 40303968 -
Autophagy
2026 Jul;22(7):1657-1678. PMID: 41968644 -
Nat Commun
Targeting de novo pyrimidine synthesis confers vulnerability to copper-mediated ATR inactivation in PARP inhibitor-resistant ovarian cancer. [Abstract]2026 Feb 25;17(1):3142. PMID: 41735312 -
J Adv Res
Antimycin A inhibits alpha-herpesvirus replication by disrupting the formation of pyrimidinosomes. [Abstract]2025 May 10:S2090-1232(25)00309-1. PMID: 40354935
Uridine purchased from MedChemExpress. Usage Cited in: J Adv Res. 2025 May 10:S2090-1232(25)00309-1. [Abstract]
Inhibitory effect of Antimycin A on BHV-1 infection was counteracted by excess uridine (10-100 μM) supplementation: MDBK cells were treated with different concentrations of Antimycin A in the presence of excess uridine at the time of BHV-1 infection (MOI = 0.5). Viral infection was quantified at 24 hpi using a Gaussia Luciferase Flash Assay.
-
Cell Death Differ
TREM2 macrophage promotes cardiac repair in myocardial infarction by reprogramming metabolism via SLC25A53. [Abstract]2024 Feb;31(2):239-253. PMID: 38182899 -
Oncogene
The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation. [Abstract]2025 May;44(16):1078-1092. PMID: 39865175 -
Cell Prolif
2023 Sep;56(9):e13442. PMID: 37086012 -
Int J Mol Sci
Uridine Alleviates Sepsis-Induced Acute Lung Injury by Inhibiting Ferroptosis of Macrophage. [Abstract]2023 Mar 7;24(6):5093. PMID: 36982166
Uridine purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 7;24(6):5093. [Abstract]
Uridine obviously weakens the expression of ACSL4, which is markedly raised in LPS group in murine lung tissues.
-
Pestic Biochem Physiol
Plumbagin targets dihydroorotase in Magnaporthe oryzae to inhibit infection and shows antifungal activity against multiple phytopathogenic fungi. [Abstract]2026 Jun:221:107096. PMID: 42264707 -
-
J Virol
African swine fever virus hijacks host pyrimidine metabolism to promote viral replication. [Abstract]2025 Nov 25;99(11):e0098525. PMID: 41171159
Uridine purchased from MedChemExpress. Usage Cited in: J Virol. 2025 Nov 25;99(11):e0098525. [Abstract]
Exogenous uridine (50 μM) supplementation restores ASFV-P30 protein levels suppressed by brequinar. For all experiments, PAMs were infected with ASFV at MOI = 1, and cell lysates were collected at 24 hpi for Western blotting.
-
Mol Immunol
Role of uridine triggering M2 macrophage polarization to alleviate LPS-induced acute lung injury through the STAT6 signaling pathway. [Abstract]2026 May 23:195:198-208. PMID: 42176493 -
ACS Chem Biol
Li-BrU-seq: A Low-Input and Simplified Metabolic Labeling Method for Nascent RNA Sequencing. [Abstract]2026 Mar 20;21(3):601-612. PMID: 41773915 -
J Pharm Biomed Anal
A novel UHPLC-MS/MS approach for simultaneous quantification of pyrimidine metabolites in human biofluids. [Abstract]2025 Nov 15:265:117026. PMID: 40544701 -
Biochem Biophys Res Commun
2026 Jan 8:795:153117. PMID: 41380445 -
-
Uridine purchased from MedChemExpress. Usage Cited in: Cell Investig. 2025 Sep 30.
Western blot analysis of EMT-related proteins (E-cadherin, N-cadherin, Vimentin, ZEB1, Slug, and Zo-1) in H1299 cells treated with uridine (ERI, 0.25-1 mM) for 48 h.
Uridine purchased from MedChemExpress. Usage Cited in: Cell Investig. 2025 Sep 30.
Uridine (0.25-1 mM; 48 h) promotes LUAD cell migration. Wound healing assay was used to detect the migration ability of A549 cells treated with uridine at different concentration for 48 h.Scale bars: 100 μm.
-
-
-
Biomed Pharmacother
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus. [Abstract]2019 Oct:118:109305. PMID: 31545264 -
Biomed Pharmacother
Antiviral activity of brequinar against foot-and-mouth disease virus infection in vitro and in vivo. [Abstract]2019 Aug:116:108982. PMID: 31146110
Uridine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2019 Aug:116:108982. [Abstract]
The viral VP1 protein and β-actin were detected by western blot. β-actin was used as an internal control. 25, 50, 200, 200 μM uridine (48 h) were added to FMDV infected IBRS-2 cells, when treated with 75 μmol/L brequinar for 48 h.
Lösungsmittel & Löslichkeit
H2O : ≥ 100 mg/mL (409.50 mM)
DMSO : 50 mg/mL (204.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (10.24 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 40 mg/mL (163.80 mM); Clear solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Reinheit & Dokumentation
-
Data Sheet (280 KB)
-
SDS (254 KB)
- English - EN (254 KB)
- Français - FR (254 KB)
- Deutsch - DE (254 KB)
- Norwegian - NO (254 KB)
- Español - ES (254 KB)
- Swedish - SV (254 KB)
- Italian - IT (254 KB)
- Korean - KR (254 KB)
- Portuguese - PT (254 KB)
-
Handling Instructions (2659 KB)
Verweise
[1]. Sokoloski JA, et al., Effects of uridine on the growth and differentiation of HL-60 leukemia cells. Leuk Res. 1991;15(11):1051-8. [Content Brief]
[2]. Zheng WV, et al., Uridine alleviates carbon tetrachloride-induced liver fibrosis by regulating the activity of liver-related cells. J Cell Mol Med. 2022 Feb;26(3):840-854. [Content Brief]
[3]. Krylova IB, et al., Uridine treatment prevents myocardial injury in rat models of acute ischemia and ischemia/reperfusion by activating the mitochondrial ATP-dependent potassium channel. Sci Rep. 2021 Aug 20;11(1):16999. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / H2O | 1 mM | 4.0950 mL | 20.4750 mL | 40.9500 mL | 102.3751 mL |
| 5 mM | 0.8190 mL | 4.0950 mL | 8.1900 mL | 20.4750 mL | |
| 10 mM | 0.4095 mL | 2.0475 mL | 4.0950 mL | 10.2375 mL | |
| 15 mM | 0.2730 mL | 1.3650 mL | 2.7300 mL | 6.8250 mL | |
| 20 mM | 0.2048 mL | 1.0238 mL | 2.0475 mL | 5.1188 mL | |
| 25 mM | 0.1638 mL | 0.8190 mL | 1.6380 mL | 4.0950 mL | |
| 30 mM | 0.1365 mL | 0.6825 mL | 1.3650 mL | 3.4125 mL | |
| 40 mM | 0.1024 mL | 0.5119 mL | 1.0238 mL | 2.5594 mL | |
| 50 mM | 0.0819 mL | 0.4095 mL | 0.8190 mL | 2.0475 mL | |
| 60 mM | 0.0683 mL | 0.3413 mL | 0.6825 mL | 1.7063 mL | |
| 80 mM | 0.0512 mL | 0.2559 mL | 0.5119 mL | 1.2797 mL | |
| 100 mM | 0.0410 mL | 0.2048 mL | 0.4095 mL | 1.0238 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Uridine Related Classifications
HY-B1449 Related Classifications
Powered by Bioz